Mrs
Dr
Miss
Ms
Prof
Printer Friendly
Printed from http://www.researchandmarkets.com/reports/1532515
Reboxetine - Key patent, SPC, and data exclusivity expiry (7 country coverage)
Description:
Pipeline Selector helps you avoid hours of painstaking research by quickly providing you with an accurate snapshot of a single INN, including key patents, extensions and data exclusivity expiry for 7 countries (44 country coverage also available), regulatory issues and key players.
This Pipeline Selector report covers Reboxetine
Reboxetine indications: Major depressive disorder
Reboxetine innovator: Pharmacia (Edronax, Vestra); Pfizer (Edronax)
Examples of information found in this online report include:
- Includes key patent publications for 7 countries (see list below)
- Contains SPC protection for every EU state plus patent term extensions in other countries
- Data exclusivity calculated on a country by country basis
- Summary of dosage forms, strengths, indications and active ingredient forms of the brand product
- DMF & Paragraph IV filings
- Litigation alerts
- Marketing authorisation holders in selected territories
- Patent risk analysis via graphical display of data from patent filings
- Hyper-linking to crucial patent documents and national registries enabling data verification
The 'Key Patent Indicator' enables easy identification of key patent, SPC and data protection expiry information covering 7 countries, including extension details (SPC and national law)(also available with 44 country coverage):
Pipeline Selector 7 Country Coverage:
Country Region Extensions
Australia Asia-Pacific S70
Canada Americas N/A
USA Americas S156
Germany Western Europe SPC
Great Britain Western Europe SPCS
France Western Europe NAT/SPC
Spain Western Europe SPC
Other key information contained in the report:
- Summary of dosage forms, strengths, indications and active ingredient forms of the brand product in major countries**.
- News articles
- Litigation alerts
- Marketing authorisation holders for Great Britain, the United States, Canada and Australia enable you to see who is active in the market.
- US Drug Master Files, providing valuable information to help source active ingredients and keep an eye on competitors.
- Paragraph IV filing; details of US ANDAs filed with a Paragraph IV certification allow easy determination of who the first movers are for a particular generic product in the US.
- 'Patent Risk Analysis' section containing three graphical displays of data drawn from known patent filings to provide valuable competitor insight and development information***.
*Key Patent Indicator
The 'Key Patent Indicator' section is intended only to provide an indication of the Key Patents pertaining to a generic drug, and is not based on a comprehensive patent search (a comprehensive patent search can be found in the corresponding Pipeline Selector report).
**General Drug Information
Information contained in 'General Indications' and 'Brand Product Attributes' is based on products containing the active pharmaceutical ingredient, which are currently registered in Australia, UK and the USA. Indications are summarised where appropriate and may vary between individual countries.
***Patent Risk Analysis
The three graphical analyses are based on data contained in our Pipeline Selector comprehensive patent search, and thus are subject to its scope and limitations. These graphics are intended to provide only a summary of the patent filings; specific details of the filings should be investigated through the use of the Pipeline Selector reports.
Pipeline Selector is just one of the benchmark products from GenericsWeb's Pipeline Patent Intelligence product suite.
This Pipeline Selector report covers Reboxetine
Reboxetine indications: Major depressive disorder
Reboxetine innovator: Pharmacia (Edronax, Vestra); Pfizer (Edronax)
Examples of information found in this online report include:
- Includes key patent publications for 7 countries (see list below)
- Contains SPC protection for every EU state plus patent term extensions in other countries
- Data exclusivity calculated on a country by country basis
- Summary of dosage forms, strengths, indications and active ingredient forms of the brand product
- DMF & Paragraph IV filings
- Litigation alerts
- Marketing authorisation holders in selected territories
- Patent risk analysis via graphical display of data from patent filings
- Hyper-linking to crucial patent documents and national registries enabling data verification
The 'Key Patent Indicator' enables easy identification of key patent, SPC and data protection expiry information covering 7 countries, including extension details (SPC and national law)(also available with 44 country coverage):
Pipeline Selector 7 Country Coverage:
Country Region Extensions
Australia Asia-Pacific S70
Canada Americas N/A
USA Americas S156
Germany Western Europe SPC
Great Britain Western Europe SPCS
France Western Europe NAT/SPC
Spain Western Europe SPC
Other key information contained in the report:
- Summary of dosage forms, strengths, indications and active ingredient forms of the brand product in major countries**.
- News articles
- Litigation alerts
- Marketing authorisation holders for Great Britain, the United States, Canada and Australia enable you to see who is active in the market.
- US Drug Master Files, providing valuable information to help source active ingredients and keep an eye on competitors.
- Paragraph IV filing; details of US ANDAs filed with a Paragraph IV certification allow easy determination of who the first movers are for a particular generic product in the US.
- 'Patent Risk Analysis' section containing three graphical displays of data drawn from known patent filings to provide valuable competitor insight and development information***.
*Key Patent Indicator
The 'Key Patent Indicator' section is intended only to provide an indication of the Key Patents pertaining to a generic drug, and is not based on a comprehensive patent search (a comprehensive patent search can be found in the corresponding Pipeline Selector report).
**General Drug Information
Information contained in 'General Indications' and 'Brand Product Attributes' is based on products containing the active pharmaceutical ingredient, which are currently registered in Australia, UK and the USA. Indications are summarised where appropriate and may vary between individual countries.
***Patent Risk Analysis
The three graphical analyses are based on data contained in our Pipeline Selector comprehensive patent search, and thus are subject to its scope and limitations. These graphics are intended to provide only a summary of the patent filings; specific details of the filings should be investigated through the use of the Pipeline Selector reports.
Pipeline Selector is just one of the benchmark products from GenericsWeb's Pipeline Patent Intelligence product suite.
Companies Mentioned
Pharmacia (Edronax, Vestra); Pfizer (Edronax)
Ordering:
Order Online - visit http://www.researchandmarkets.com/reports/1582661
Order by Fax - using the order form below
Order By Post - print the order form below and send to
Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Page 1 of 2
Printed Friday, May 24, 2013
12:24:39 PM
12:24:39 PM
Fax order form
To place a fax order simply print this form, fill in and fax the completed form to the number below. If you have any questions please email help@researchandmarkets.net
Order information
Please verify that the product information is correct and select the format you require.
Product name
Reboxetine - Key patent, SPC, and data exclusivity expiry (7 country coverage)
Web Address
http://www.researchandmarkets.com/reports/1532515
Office Code
OC8DIQSNOONTUS
Report Formats
Please enter the quantity of the report format you require.
| Format | Quantity | Price | Electronic (Online Access) - Single User |
|
EURO€ 384.00 |
|---|
Contact information
Please enter all the information below in block capitals.
Title:
Mr
Mrs
Dr
Miss
Ms
Prof
Mrs
Dr
Miss
Ms
Prof
First Name:
Last Name:
Email Address:
Job Title:
Organisation:
Address:
City:
Postal / Zip Code:
Country:
Phone Number:
Fax Number:
Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)
Page 2 of 2
Printed Friday, May 24, 2013
12:24:39 PM
12:24:39 PM
Payment information
Please indicate the payment method you would like to use by selecting the appropriate box.
Pay by Credit Card:
American Express
Diners Club
Master Card
Visa
Cardholder's Name:
Cardholder's Signature:
Expiry Date:
/
Card Number:
CVV Security Code:
Issue date:
/ (Diners Club only)
Pay by Check:
Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Pay by Wire Transfer:
Please transfer funds to:
Account Number:
83313083
Sort Code:
98-53-30
Swift Code:
ULSBIE2D
IBAN Number:
IE78ULSB98533083313083
Bank Address:
Ulster Bank,
27-35 Main Street
Blackrock,
Co. Dublin
Ireland.
27-35 Main Street
Blackrock,
Co. Dublin
Ireland.
If you have a Marketing Code please enter it below:
Marketing Code:
Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp